Wegovy Cut Children's BMI by 17.4% in Novo's Late-Stage Trial
Wegovy cut BMI 17.4% in children ages 6 to under 12 over 68 weeks, Novo's full trial results show, with over 40% no longer classified as having obesity — a group with no approved obesity drugs today.
By Nathan Brooks
3 min read

What's News
- Wegovy reduced BMI by 19.7 percentage points vs placebo at 68 weeks in children ages 6 to under 12.
- More than 40% of children on Wegovy were no longer classified as having obesity after 68 weeks.
- 177 million children and teens ages 5-19 had obesity in 2025, projected to reach 228 million by 2040.
- No approved obesity medications currently exist for children under 12.
- Novo reported no safety concerns on growth or pubertal development in the 167-child trial.
Novo Nordisk's Wegovy reduced body mass index by 19.7 percentage points versus a placebo in children ages 6 to under 12, according to full late-stage trial results released Monday. BMI fell 17.4% among children on the drug over 68 weeks, while it rose 2.2% among those on placebo.
Those figures assume patients stayed on treatment. When Novo counted every child in the study, including those who discontinued the drug, Wegovy still beat placebo by an estimated 16.2 percentage points at 68 weeks.
The trial enrolled 167 children. All of them received lifestyle interventions throughout — a reduced-calorie diet and increased physical activity — meaning the drug's effect was measured on top of standard counseling, not instead of it.
What does this change for younger children?
Plenty, because the under-12 group currently has zero approved obesity medications. Wegovy is already cleared for children 12 and older, so these results position Novo to fill a treatment gap for kids as young as 6, safely and effectively reducing disease severity in a population that has had few options beyond lifestyle changes.
The disease burden is large and growing. Roughly 177 million children and teens ages 5 to 19 worldwide lived with obesity in 2025, according to the World Obesity Federation. That number is projected to reach 228 million by 2040 — roughly one in four more cases in 15 years.
Childhood obesity is a chronic disease with cardiovascular, metabolic and psychosocial consequences, and it often extends into adulthood, bringing earlier and more severe complications.
"This is a very significant disease burden in this very young patient population," said Dr. Andrea Traina, Novo's medical director lead of obesity.
Who were the kids in the trial?
This was not a mildly overweight population. The trial's profile:
- 85% of children started with moderate to severe obesity — BMI thresholds of 35 and above, and 40 or higher, respectively.
- Nearly half already had at least one obesity-related complication such as high blood pressure, high cholesterol or sleep apnea.
- More than 40% of children treated with Wegovy were no longer classified as having obesity after 68 weeks, assuming they stayed on treatment.
Novo first shared that 40% remission figure in September.
"We are driving towards control of this chronic disease in that patient population when they are still so young and at such high risk for more advanced and accelerated disease progression because they developed it so early," Traina said.
Safety, and the open questions
Safety looked clean by the company's account. Novo said Wegovy's overall safety and tolerability in children — how well patients managed the drug — matched what was seen in adult trials. The company reported no safety concerns related to growth or pubertal development.
But the two-year study leaves a big question unanswered: whether treating obesity this early actually changes the disease's long-term trajectory. Doctors also don't yet know what treatment and maintenance should look like as these children grow into adulthood, Traina said.
"That is something that is still an evidence gap," she said, pointing to the potential of future research.
For practitioners and payers, the takeaway is straightforward. Wegovy now has late-stage evidence in 6-to-11-year-olds showing a 17.4% average BMI reduction and obesity remission in over 40% of treated kids, with adult-comparable safety. What's still missing — and what future research will have to establish — is whether starting this early rewrites the disease's course over a lifetime.
Source: CNBC Business
More from Nathan Brooks
Show full bio
News editor covering regulation, policy and their impact on entrepreneurship, startups and venture funding at Business Bearings.
2,231 articles